Can a 5 mg enalapril tablet be split to obtain a lower dose in an adult with severe chronic kidney disease (eGFR <30 mL/min/1.73 m²)?

Can You Split a 5 mg Enalapril Tablet in Severe CKD?

Yes, you can and should split a 5 mg enalapril tablet to obtain a 2.5 mg starting dose in patients with severe chronic kidney disease (eGFR <30 mL/min/1.73 m²). This is the recommended initial dose for ACE inhibitor therapy in advanced renal impairment. 1

Dosing Algorithm for Enalapril in Severe CKD

Initial Dose Reduction Required

• Start at 2.5 mg once daily (half of the standard 5 mg starting dose) when eGFR is 10–30 mL/min/1.73 m². 1
• This dose reduction is mandatory because renal clearance of enalapril and its active metabolite enalaprilat is markedly decreased in advanced CKD, increasing the risk of hypotension, hyperkalemia, and acute kidney injury. 2, 1
• The standard 5 mg starting dose should not be used in patients with eGFR <30 mL/min/1.73 m². 1

Practical Splitting Method

• Split the 5 mg tablet in half to obtain approximately 2.5 mg per dose. 1
• Most enalapril 5 mg tablets are scored and designed to be split accurately.
• If precise splitting is difficult, consider requesting a pharmacy compound 2.5 mg capsules or prescribing commercially available 2.5 mg tablets if formulary permits.

Titration Schedule After Initiation

• Check serum potassium and eGFR within 1 week of starting the 2.5 mg dose. 2, 1
• If tolerated (potassium ≤5.5 mmol/L, eGFR decline <30% from baseline, blood pressure adequate), continue 2.5 mg daily for 2–4 weeks. 1
• Uptitrate by 2.5 mg increments every 2–4 weeks if blood pressure control remains inadequate and laboratory parameters are stable. 1
• The maximum target dose remains 40 mg daily even in severe renal impairment, though most patients with eGFR <30 mL/min/1.73 m² require only 5–20 mg. 1

Evidence Supporting Lower Doses in Advanced CKD

Research Demonstrating Efficacy of Low-Dose Enalapril

• A randomized trial in patients with median GFR 17 mL/min/1.73 m² compared high-dose (median 10 mg daily) versus low-dose (median 1.88 mg daily) enalapril over 12 months. 3
• Low-dose enalapril provided equivalent renoprotection, blood pressure control, and proteinuria reduction compared to high-dose therapy (mean GFR decline 4.3 vs. 6.1 mL/min/1.73 m² per year, p=0.48). 3
• Importantly, five patients in the high-dose group reached end-stage renal disease versus zero in the low-dose group (p=0.04), and hyperkalemia was significantly more common with high doses. 3
• This evidence strongly supports starting at the lowest effective dose and titrating cautiously based on clinical response rather than automatically escalating to standard doses. 3

Initial GFR Decline Is Expected and Acceptable

• A study of 31 patients with severe chronic nephropathy (median GFR 14 mL/min/1.73 m²) showed that enalapril (mean dose 9 mg) caused a median 14% decline in GFR within 24 hours of initiation. 4
• This acute decline was clinically acceptable in most patients and reflects hemodynamic changes from reduced intraglomerular pressure—the mechanism underlying long-term nephroprotection. 4
• An acute GFR decline up to 30% is tolerable and should not prompt discontinuation unless accompanied by hyperkalemia or symptomatic hypotension. 2, 1

Mandatory Monitoring Protocol

Week 1 Assessment

• Measure serum potassium and eGFR within 7 days of starting or changing the enalapril dose. 2, 1
• Hold enalapril if potassium >5.5 mmol/L or eGFR declines >30% from baseline. 1

Ongoing Surveillance

• Monthly monitoring of potassium and eGFR for the first 3 months, then every 3 months if stable. 1
• Reduce or discontinue potassium supplements when initiating enalapril to mitigate hyperkalemia risk. 2, 1
• Educate patients to avoid over-the-counter potassium supplements, potassium-based salt substitutes, and high-potassium foods. 2

Temporary Suspension Criteria

• Hold enalapril during:
  • Acute illness, dehydration, or diarrhea 2, 1
  • Planned IV radiocontrast administration 2
  • Bowel preparation prior to colonoscopy 2
  • Major surgery 2
  • Serum potassium >5.5 mmol/L 1
  • Acute kidney injury 1

Critical Pitfalls to Avoid

Do Not Discontinue ACE Inhibitors Solely Because eGFR <30 mL/min/1.73 m²

• RAAS antagonists should not be routinely discontinued when eGFR falls below 30 mL/min/1.73 m² because nephroprotective effects persist at low GFR. 2, 1
• The KDOQI guidelines explicitly state that ACE inhibitors remain nephroprotective in advanced CKD and should be continued with appropriate monitoring. 2

Do Not Start at Standard 5 mg Dose

• Beginning at 5 mg daily in severe CKD increases the risk of hyperkalemia, hypotension, and excessive GFR decline. 1
• Always split the tablet or prescribe 2.5 mg to initiate therapy safely. 1

Do Not Combine with Other RAAS Blockers

• Dual RAAS blockade (ACE inhibitor plus ARB, or ACE inhibitor plus aldosterone antagonist) in patients with eGFR <30 mL/min/1.73 m² markedly increases hyperkalemia risk. 2
• A study of dual blockade with enalapril 20 mg and candesartan 16 mg in CKD stage 3–5 patients found that 45% did not tolerate the combination, primarily due to loss of renal function or hypotension. 5
• The triple combination of ACE inhibitor, ARB, and mineralocorticoid receptor antagonist is explicitly discouraged. 2

Do Not Continue Potassium Supplements Without Close Monitoring

• Hyperkalemia risk is substantially elevated in advanced CKD, and concomitant potassium supplementation often precipitates dangerous elevations. 2, 1
• Review and discontinue potassium supplements before starting enalapril. 1

Avoid Concomitant Nephrotoxic Agents

• NSAIDs should be avoided in patients with eGFR <30 mL/min/1.73 m² taking ACE inhibitors, as the combination increases acute kidney injury risk. 2
• Aminoglycosides and other nephrotoxic antibiotics require dose adjustment and close monitoring. 2

Summary Algorithm: Enalapril Initiation in Severe CKD

Step	Action	Monitoring
1. Baseline	Check eGFR, potassium, blood pressure	Document baseline values
2. Initiation	Split 5 mg tablet; give 2.5 mg once daily	Educate on potassium avoidance
3. Week 1	Recheck potassium and eGFR	Hold if K⁺ >5.5 mmol/L or eGFR ↓ >30%
4. Weeks 2–4	Continue 2.5 mg if tolerated	Monitor blood pressure
5. Titration	Increase by 2.5 mg every 2–4 weeks if BP inadequate	Recheck K⁺ and eGFR with each increase
6. Maintenance	Target 5–20 mg daily (rarely >20 mg needed)	Monthly labs × 3 months, then quarterly

This algorithm is derived from KDOQI guidelines and ACC/AHA recommendations for RAAS inhibitor use in advanced CKD. 2, 1